Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
24 participants
INTERVENTIONAL
2025-07-31
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To compare the levels of stress-related biomarkers before and after relaxing VR-content (Relax Visit);
* To compare the levels of stress-related biomarkers before and after stress-inducing VR-content (Rollercoaster Visit).
Researchers will compare the Relax and Rollercoaster Visit to see if there is a relationship between the relaxing and stress-inducing VR content on stress-related blood values.
Participants will be asked to watch relaxing or stress-inducing VR content for approximately five minutes. Blood will be withdrawn before and after intervention. After 3-5 weeks the study visit will be repeated using the other VR content.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Virtual Reality as a Tool to Lower Blood Pressure and Anxiety in Clinic Settings
NCT06960057
Assessing the Acute Effects of Virtual Reality Interventions on Stress
NCT07191288
Healthy Volunteer Undergoing Painful Stimuli With and Without Hypnosis and Virtual Reality
NCT04107558
Virtual Reality for Children's Blood Sampling
NCT04472507
Virtual Reality to Reduce Intra-procedural Anxiety and Sedation Needs During Procedures
NCT04279665
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: To assess the impact of exposure to relaxing and stress-inducing virtual reality content on the levels of stress-related biomarkers in healthy individuals.
Study design: This is a monocentre pilot cross-over clinical trial. Study participants will be randomly assigned to one of the two arms. These arms determine the order of VR content exposure. The first arm will be exposed to relaxing VR content during the first study visit, during which blood will be drawn before and after the VR experience. Then, after an interval of 3-5 weeks, they will be exposed to stress-inducing VR content and blood will be drawn before and after. The second arm will do the study visits in the opposite order.
Study population: Healthy volunteers between the ages of 18 and 45 years with no medical history on haematologic, endocrinologic or cardiac disorders.
Intervention:
Participants will be exposed to stress-inducing and relaxing VR content during two separate study visits, the Relax Visit and the Rollercoaster Visit. Blood samples will be collected immediately before and after each VR session to measure changes in stress-related biomarkers. Additionally, objective stress levels measured by vital functions (e.g. heart rate, blood pressure) and subjective stress levels measured using a visual analogue scale (VAS) will be collected immediately pre- and post- VR exposure.
Main study parameters/endpoints:
The correlation between stress-related biomarkers (factor VIII activity, vWF ristocetin co-factor activity, copeptin (AVP), prolactin, thyroid stimulating hormone (TSH), cortisol and glucose) before and after relaxing and stress-inducing VR-content.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Participation includes two site visits, with an interval of 3 to 5 weeks. In both visits blood samples will be collected immediately before and after each VR session to measure changes in biomarkers. Additionally, objective stress levels measured by vital functions and subjective stress levels measured using a visual analogue scale will be collected immediately pre- and post- VR exposure. There are no benefits for participants. However, the results of this study may possibly benefit patients with haematological and endocrinological disorders regarding their comfort and anxiety during blood sampling and by reducing unnecessary extra sampling. Furthermore, it may benefit their treatment by optimizing the diagnostic process. Potential risks are the experience of motion-sickness during the VR experience and a blood withdrawal might be experienced as minimally painful for a very short amount of time. However, to minimalize this pain participants will apply a numbing cream one hour before the start of a study visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Arm A receives the Relax visit first and 3-5 weeks later the Rollercoaster Visit.
Meditation video at the beach
A virtual reality video consisting of a 5 minute meditation video at te beach.
Rollercoaster video
A virtual reality video consisting of a five minute rollercoaster ride.
Arm B
Arm B receives the Rollercoaster Visit first and 3-5 weeks later the Relax Visit.
Meditation video at the beach
A virtual reality video consisting of a 5 minute meditation video at te beach.
Rollercoaster video
A virtual reality video consisting of a five minute rollercoaster ride.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Meditation video at the beach
A virtual reality video consisting of a 5 minute meditation video at te beach.
Rollercoaster video
A virtual reality video consisting of a five minute rollercoaster ride.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to provide written informed consent.
Exclusion Criteria
* Fear of needles;
* Any of the following haematological disorders:
* Congenital or acquired haemophilia A;
* Von Willebrand Disease.
* Any of the following endocrinological disorders:
* Thyroid disorders (e.g. hypo/hyperthyroidism);
* Cushing syndrome;
* Adrenal insufficiency;
* Diabetes mellitus type 1 or 2;
* Central or nephrogenic AVP deficiency.
* A confirmed cardiac disorder;
* All types of epilepsy;
* Every form of medication, except for intermittent use of pain killers but not in the last week (e.g. paracetamol) and an intra-uterine device with or without contraceptive;
* Pregnancy.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Van Creveldkliniek
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Van Creveldkliniek
Center for Benign Hematology, Thrombosis and Haemostasis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Corien L. Eckhardt, MD PhD
Role: PRINCIPAL_INVESTIGATOR
UMC Utrecht
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Centre Utrecht
Utrecht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL-009813
Identifier Type: REGISTRY
Identifier Source: secondary_id
25U-0212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.